TABLE 6.
Amikacin inhalation therapy for refractory nontuberculous mycobacterial lung disease in previous case seriesa
| Treatment and author(s), year (reference) | No. of patients | Organism (no. of patients) | Median (IQR) treatment duration before AMK inhalation (mo) | % of patients with macrolide- resistant isolates (no. of patients with macrolide-resistant isolates/total no. of patients) | Median (IQR) duration of AMK inhalation (mo) | % of patients intolerant of AMK inhalation (no. of patients with intolerance/total no. of patients) | % of patients with sputum conversion (no. of patients with sputum conversion/total no. of patients) |
|---|---|---|---|---|---|---|---|
| Amikacin inhalation | |||||||
| Davis et al., 2007 (13) | 6 | MAC (6) | 24.5 (9.1–60.0) | 0 (0/6) | 11.0 (7.0–25.0) | 33 (2/6) | 67 (4/6) |
| Safdar, 2012 (14) | 9 | MAC (2) | ≥3.0 | NA | 2.5 (1.5–5.9) | 11 (1/9) | NAb |
| MABC (3) | |||||||
| M. kansasii (3) | |||||||
| MAC + MABC (1) | |||||||
| Olivier et al., 2014 (15) | 20 | MAC (5) | 60.0 | 75 (15/20) | 19.0 | 35 (7/20) | 25 (5/20) |
| MABC (15) | 6.0–190.0c | 1.0–50.0c | |||||
| Yagi et al., 2017 (16) | 26 | MAC (23) | 61.0 (28.0–107.0) | 39 (9/23) | 7.0 (6.0–12.3) | 8 (2/26) | 43 (10/23)d |
| MABC (3) | |||||||
| This study | 77 | MAC (20) | 37.8 (15.7–61.4) | 82 (63/77) | 12.0 (6.8–12.0) | 38 (29/77) | 18 (14/77) |
| MABC (48) | |||||||
| MAC + MABC (9) | |||||||
| Liposomal amikacin inhalation, Olivier et al., 2017 (17) | 44 | MAC (29) | ≥12.0 | 18 (8/44) | ≥6.0 | 18 (8/44) | 32 (14/44) |
| MABC (15) |
a
Abbreviations: AMK, amikacin; MAC, M. avium complex; MABC, M. abscessus complex; IQR, interquartile range; NA, not available.
b
All patients demonstrated complete (n = 8) or partial (n = 1) clinicoradiographic responses.
c
Values are ranges.
d
Sputum conversion could not be evaluated in three patients.